| Autor: |
Herrera Estrada, Lina, Wu, Huixia, Ling, Kevin, Zhang, Guikai, Sumagin, Ronen, Parkos, Charles A., Jones, Rheinallt M., Champion, Julie A., Neish, Andrew S. |
| Zdroj: |
ACS Nano; September 2017, Vol. 11 Issue: 10 p9650-9662, 13p |
| Abstrakt: |
Bacterial enteric pathogens have evolved efficient mechanisms to suppress mammalian inflammatory and immunoregulatory pathways. By exploiting the evolutionary relationship between the gut and pathogenic bacteria, we have developed a potential mucosal therapeutic. Our findings suggest that engineered preparations of the Salmonellaacetyltransferase, AvrA, suppress acute inflammatory responses such as those observed in inflammatory bowel disease (IBD). We created 125 nm diameter cross-linked protein nanoparticles directly from AvrA and carrier protein to deliver AvrA in the absence of Salmonella. AvrA nanoparticles are internalized in vitroand in vivointo barrier epithelial and lamina propria monocytic cells. AvrA nanoparticles inhibit inflammatory signaling and confer cytoprotection in vitro, and in murine colitis models, we observe decreased clinical and histological indices of inflammation. Thus, we have combined naturally evolved immunomodulatory proteins with modern bioengineering to produce AvrA nanoparticles, a potential treatment for IBD. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
